

Independent Auditor's Review Report on Standalone unaudited financial results of Advanced Enzyme Technologies Limited for the quarter pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors of Advanced Enzyme Technologies Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results of Advanced Enzyme Technologies Limited (hereinafter referred to as 'the Company') for the quarter ended June 30, 2024 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Regulations').
2. This Statement, which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder ('Ind AS 34') and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M S K A & Associates

Chartered Accountants

ICAI Firm Registration No.105047W



Amrish Vaidya

Partner

Membership No.: 101739

UDIN: 24101739BKKEZTQ9767



Place: Ongole

Date: August 10, 2024

Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.

Tel No: 91-22-41703220 Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

Statement of Unaudited standalone financial results for the quarter ended 30 June 2024

(₹ in Million except per share data)

Particulars	Quarter ended			Year ended
	30-Jun-24 Unaudited	31-Mar-24 Audited (Refer note V)	30-Jun-23 Unaudited	31-Mar-24 Audited
1 Revenue from operations	859.57	924.03	853.49	3,654.69
2 Other Income	538.76	32.10	512.49	588.09
3 Total Income (1+2)	1,398.33	956.13	1,365.98	4,242.78
4 Expenses				
(a) Cost of materials consumed	375.80	334.45	352.88	1,395.61
(b) Purchases of stock-in-trade	-	-	-	-
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(61.58)	(19.46)	(60.88)	(78.34)
(d) Employee benefits expense (refer note iii)	141.90	133.91	113.47	493.88
(e) Finance costs (including exchange difference)	0.22	0.48	0.35	1.57
(f) Depreciation and amortisation expense	26.19	30.67	25.07	108.98
(g) Other expenses	194.24	182.69	200.25	791.68
Total expenses	676.77	662.74	631.14	2,713.38
5 Profit before exceptional item and tax (3-4)	721.56	293.39	734.84	1,529.40
6 Exceptional item (refer note viii)	-	189.48	-	189.48
7 Profit before tax (5-6)	721.56	103.91	734.84	1,339.92
8 Tax expense				
Current tax	49.46	75.36	60.65	269.51
Deferred tax charge/(credit)	1.54	(2.83)	(0.68)	(10.82)
Total tax expense	51.00	72.53	59.97	258.69
9 Net profit for the period (7-8)	670.56	31.38	674.87	1,081.23
10 Other comprehensive income				
A (i) Items that will not be reclassified to Profit or Loss				
Remeasurements of defined benefit liability/(asset)	-	(1.38)	-	(1.38)
(ii) Income tax related to items that will not be reclassified to Profit or Loss	-	0.35	-	0.35
B (i) Items that will be reclassified to Profit or Loss	-	-	-	-
(ii) Income tax related to items that will be reclassified to Profit or Loss	-	-	-	-
Total Other comprehensive income	-	(1.03)	-	(1.03)
11 Total comprehensive income (9+10)	670.56	30.35	674.87	1,080.20
12 Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	223.65	223.65	223.65	223.65
13 Other equity				5,581.06
14 Earnings Per Share of ₹ 2 each (not annualized)				
(a) ₹ (Basic)	6.00	0.28	6.04	9.67
(b) ₹ (Diluted)	5.99	0.28	6.04	9.66



Advanced Enzyme Technologies Limited

CIN No: L24200MH1989PLC051018

Head Office and Corporate Office: Sun Magnetica, 5th Floor, Near IIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.

Tel No: 91-22-41703220 Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

Notes:

- (i) The above standalone financial results of Advanced Enzyme Technologies Limited ('the Company') were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 10 August 2024. The above results have been subjected to 'limited review' by the statutory auditors of the Company and they have expressed an unmodified conclusion. The limited review report will be filed with stock exchanges and will be available on the Company's website. The above results has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies in India.
- (ii) The Company operates only in one business segment viz 'manufacturing and sales of enzymes'.
- (iii) The Shareholders at its Annual General meeting held on 19 August 2022 approved the Employee Stock Option Scheme 2022 ('ESOP Scheme 2022') of the Company and its extension to the subsidiaries of the Company. National Stock Exchange of India Limited and BSE Limited (Stock Exchanges) vide their letter/e-letter dated 06 October 2022 and 18 October 2022 respectively granted its 'In-Principle' approval for listing of 2,500,000 Equity Shares of Rs. 2 each which may arise out of exercise of Options as and when exercised from time to time subject to the prescribed conditions. The Company has granted 576,000 options under Employee Stock Option Scheme 2022 ('ESOP Scheme 2022') on 12 August 2023, approved by Nomination and Remuneration Committee of the Board.
- (iv) On 5 March 2024, the Company has acquired stake of 5.89% in its subsidiary JC Biotech Private Limited for a consideration of Rs 56.07 million. Post this acquisition the Company holds 95.72% stake in the subsidiary.
- (v) The figures for the quarter ended 31 March 2024 are the balancing figures between standalone audited figures in respect of the full financial year and the published year to date figures upto the end of the third quarter of the relevant financial year. Also, the figures up to the end of the third quarter had only been reviewed and not subjected to audit.
- (vi) The Board of Directors of the Company declared and paid interim dividend of Rs 4/- per equity share during the quarter.
- (vii) The final dividend for the financial year 2023-24 of Rs 1.10/- per equity share is paid on 31 July 2024 after approval of the shareholders of the Company in its Annual General Meeting held on 25 July 2024.
- (viii) During Annual audit for the financial year 2023-24, the Company had carried out fair value assessment of its investment in Advanced Enzymes Europe B.V. (AEEBV) and after considering past business performance, prevailing business conditions and revised expectations of its future performance and this assessment has resulted in impairment loss of Rs. 189.48 million of investment in the subsidiary.
- (ix) Previous year / period amounts have been regrouped / reclassified wherever necessary.

Place: Ongole

Dated: 10 August 2024



By Order of the Board of Directors

For Advanced Enzyme Technologies Limited

CIN: L24200MH1989PLC051018

M. M. Kabra

M. M. Kabra

Wholtime Director

DIN : 00148294